Aligos Therapeutics reports a Schedule 13G filing disclosing beneficial ownership by Lawrence M. Blatt. The filing states the Reporting Person beneficially owns 286,213 shares of Common Stock, representing 5.1% of the class, based on 5,388,223 shares outstanding as of May 1, 2026.
The ownership mix includes directly held shares, trusts, an IRA, 12,206 shares underlying exercisable warrants, and 185,591 shares underlying stock options exercisable or exercisable within 60 days of March 31, 2026.
Positive
None.
Negative
None.
Insights
Filing discloses a 5.1% beneficial stake through mixed holdings.
The filing lists 286,213 shares beneficially owned by Lawrence M. Blatt as of March 31, 2026, using an outstanding share base of 5,388,223 as of May 1, 2026. The position combines direct holdings, trusts, an IRA, 12,206 warrants, and 185,591 options exercisable within 60 days.
Cash‑flow treatment and any planned dispositions are not stated; subsequent filings would disclose transactional activity if it occurs. Ownership concentration near 5% can be relevant for governance disclosures and potential Schedule 13D thresholds.
Key Figures
Beneficially owned shares:286,213 sharesPercent of class:5.1%Shares outstanding:5,388,223 shares+2 more
5 metrics
Beneficially owned shares286,213 sharesBeneficial ownership as of March 31, 2026
Percent of class5.1%Percent of common stock based on outstanding shares as of May 1, 2026
Shares outstanding5,388,223 sharesShares outstanding as of May 1, 2026 (used for percent calculation)
Options exercisable185,591 sharesOptions exercisable or exercisable within 60 days of March 31, 2026
Warrants exercisable12,206 sharesShares held by exercisable warrants
Key Terms
Beneficially owned, Shares underlying stock options, Exercisable warrants, As of date
4 terms
Beneficially ownedregulatory
"The Reporting Person is the beneficial owner of 286,213 shares of Common Stock"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shares underlying stock optionsfinancial
"185,591 shares of Common Stock underlying stock options held directly by the Reporting Person"
Exercisable warrantsfinancial
"12,206 shares of common stock held by exercisable warrants"
As of dateregulatory
"beneficial ownership of Common Stock of the Issuer as of March 31, 2026"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Aligos Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value, $0.0001 per share
(Title of Class of Securities)
01626L204
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
01626L204
1
Names of Reporting Persons
Lawrence M. Blatt
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
286,213.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
286,213.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
286,213.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Aligos Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
One Corporate Drive, 2nd Floor, South San Francisco, CA 94080
Item 2.
(a)
Name of person filing:
This Schedule 13G is filed on behalf of Lawrence M. Blatt (the "Reporting Person").
(b)
Address or principal business office or, if none, residence:
The Reporting Person's principal business address is c/o Aligos Therapeutics, Inc., One Corporate Drive, 2nd Floor, South San Francisco, CA 94080.
(c)
Citizenship:
The Reporting Person is a citizen of the United States.
(d)
Title of class of securities:
Common Stock, par value, $0.0001 per share
(e)
CUSIP Number(s):
01626L204
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The ownership information presented herein represents beneficial ownership of Common Stock of the Issuer as of March 31, 2026, based upon 5,388,223 shares of voting Common Stock outstanding as of May 1, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed on May 7, 2026.
The Reporting Person is the beneficial owner of 286,213 shares of Common Stock, which consist of (i) 3,251 shares of Common Stock held directly by the Reporting Person, (ii) 78,781 shares of Common Stock held by Lawrence M. Blatt Living Trust dated 8/27/2014, (iii) 4,904 shares of Common Stock held by PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA, (iv) 740 shares of Common Stock held by Zachary David Blatt Irrevocable Trust dated 8/24/2014, (v) 740 shares of Common Stock held by Zoe Anne Blatt Irrevocable Trust dated 8/24/2014, (vi) 12,206 shares of common stock held by exercisable warrants and (vii) 185,591 shares of Common Stock underlying stock options held directly by the Reporting Person that are currently exercisable or may be exercised within 60 days of March 31, 2026.
(b)
Percent of class:
5.1%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
286,213
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
286,213
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
Not Applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
The filing reports Lawrence M. Blatt beneficially owns 286,213 shares, representing 5.1% of the outstanding common stock based on 5,388,223 shares outstanding as of May 1, 2026. The holding combines direct shares, trusts, an IRA, warrants, and options.
How are Mr. Blatt's 286,213 shares composed?
The 286,213 shares include 3,251 direct shares, trust holdings (78,781), an IRA (4,904), two family irrevocable trusts (740 each), 12,206 shares from exercisable warrants, and 185,591 shares from options exercisable within 60 days.
What outstanding share count did the filing use to compute 5.1%?
The percentage is calculated using 5,388,223 shares outstanding as disclosed in the issuer's Form 10‑Q filed May 7, 2026, with the outstanding count dated May 1, 2026. That outstanding figure is the base for the 5.1% calculation.
Do the filing details show any recent purchases or sales?
The Schedule 13G excerpt reports beneficial ownership as of March 31, 2026 but does not disclose any purchase or sale transactions. It lists holdings and exercisable derivatives; no transactional activity or intent to trade is stated in the provided text.
Are the option and warrant shares currently exercisable?
The filing states 12,206 shares are held by exercisable warrants and 185,591 shares under stock options that are currently exercisable or may be exercised within 60 days of March 31, 2026, indicating near‑term exercisability for those derivative instruments.
